PhaseBio Pharmaceuticals Inc

2018 Q4 Form 10-Q Financial Statement

#000156459018030291 Filed on November 29, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.00M $24.30M
YoY Change
Cash & Equivalents $61.03M $24.34M $4.277M
Short-Term Investments
Other Short-Term Assets $1.300M $200.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $233.0K $411.0K
Total Short-Term Assets $62.63M $24.97M
YoY Change 354.95%
LONG-TERM ASSETS
Property, Plant & Equipment $355.0K $251.0K
YoY Change 17.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $43.00K $51.00K
YoY Change 38.71%
Total Long-Term Assets $398.0K $2.520M
YoY Change 19.52%
TOTAL ASSETS
Total Short-Term Assets $62.63M $24.97M
Total Long-Term Assets $398.0K $2.520M
Total Assets $63.03M $27.49M
YoY Change 347.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.806M $1.576M
YoY Change 320.0%
Accrued Expenses $2.771M $2.987M
YoY Change 116.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $3.125M
YoY Change -100.0%
Total Short-Term Liabilities $4.577M $7.688M
YoY Change -73.99%
LONG-TERM LIABILITIES
Long-Term Debt $7.500M $4.375M
YoY Change 185.71%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $7.500M $4.375M
YoY Change 185.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.577M $7.688M
Total Long-Term Liabilities $7.500M $4.375M
Total Liabilities $12.10M $18.05M
YoY Change -44.71%
SHAREHOLDERS EQUITY
Retained Earnings -$122.9M -$118.0M
YoY Change 24.07%
Common Stock $25.00K $1.000K
YoY Change 2400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.00K $24.00K
YoY Change 0.0%
Treasury Stock Shares 29.97K shares $29.97K
Shareholders Equity $50.93M -$116.2M
YoY Change
Total Liabilities & Shareholders Equity $63.03M $27.49M
YoY Change 347.02%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24341000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13406000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
761000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1576000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
430000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7688000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17595000
CY2018Q3 us-gaap Liabilities
Liabilities
18053000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
411000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
340000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
24968000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
13746000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
251000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
302000
CY2018Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2218000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000
CY2018Q3 us-gaap Assets
Assets
27488000
CY2017Q4 us-gaap Assets
Assets
14099000
CY2017Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12095000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3028000
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3125000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2987000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1281000
CY2018Q3 phas Preferred Stock Warrant Liability
PreferredStockWarrantLiability
5990000
CY2017Q4 phas Preferred Stock Warrant Liability
PreferredStockWarrantLiability
1656000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5000
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4375000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2625000
CY2017Q4 us-gaap Liabilities
Liabilities
21881000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
125609295
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
89633543
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-359000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24498275
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q3 us-gaap Treasury Stock Value
TreasuryStockValue
24000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118043000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-116174000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27488000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1892000
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1672000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99065000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-97416000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14099000
CY2018Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
18292696
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13321350
CY2018Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
13200115
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9131999
CY2018Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
13200115
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9131999
CY2018Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
129071361
CY2017Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
89776055
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20789273
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20789273
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
795640
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
775755
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
765673
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
745788
CY2018Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
411000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
411000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4354000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1330000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9779000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4387000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1056000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
565000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2616000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
5410000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
1895000
us-gaap Operating Expenses
OperatingExpenses
12395000
us-gaap Operating Expenses
OperatingExpenses
6087000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4999000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1895000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11984000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000
us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2017Q3 us-gaap Interest Expense
InterestExpense
618000
us-gaap Interest Expense
InterestExpense
3741000
us-gaap Interest Expense
InterestExpense
1605000
CY2018Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1713000
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2709000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-130000
CY2017Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-66000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-676000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-179000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2902000
us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
95000
us-gaap Profit Loss
ProfitLoss
-18978000
us-gaap Profit Loss
ProfitLoss
-7712000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-665000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6994000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1625000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7901000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2560000
us-gaap Net Income Loss
NetIncomeLoss
-18978000
us-gaap Net Income Loss
NetIncomeLoss
-7712000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.45
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.38
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
755908
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
743241
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
749198
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
743241
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
262000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
82000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000
us-gaap Share Based Compensation
ShareBasedCompensation
262000
us-gaap Share Based Compensation
ShareBasedCompensation
58000
us-gaap Paid In Kind Interest
PaidInKindInterest
3580000
us-gaap Paid In Kind Interest
PaidInKindInterest
1605000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
411000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-130000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
67000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
558000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-39000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1182000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
204000
phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-5000
phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10215000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5835000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
204000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-204000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
17712000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
3995000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
595000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
53000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
6601000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21181000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6601000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10935000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
562000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3715000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4277000
us-gaap Interest Paid Net
InterestPaidNet
161000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
19778000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2822000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1046000
phas Stock Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction
StockIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction
1623000
phas Warrant Liability Converted To Redeemable Convertible Preferred Stock Upon Exercise Of Warrants
WarrantLiabilityConvertedToRedeemableConvertiblePreferredStockUponExerciseOfWarrants
1196000
phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
95000
phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
50000
phas Issuance Of Derivative In Conjunction With Debt
IssuanceOfDerivativeInConjunctionWithDebt
1309000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed financial statements relate to the valuation of redeemable convertible preferred stock warrants, equity awards and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposits in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</p>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effected a 11.0634-for-1 reverse split of its outstanding common stock and redeemable convertible preferred stock.
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24300000
CY2018Q3 phas Working Capital
WorkingCapital
17300000
CY2018Q3 us-gaap Restricted Cash
RestrictedCash
20000
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
20000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15224224
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10485467
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1978000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1947000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1727000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1645000
CY2018Q3 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
1335000
CY2017Q4 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
197000
CY2018Q3 phas Accrued Stock Offering Costs Current
AccruedStockOfferingCostsCurrent
1041000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
261000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
346000
CY2018Q3 us-gaap Interest Payable Current
InterestPayableCurrent
110000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
628000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
240000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
110000
CY2018Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3750000
CY2018Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3750000
CY2018Q3 us-gaap Long Term Debt
LongTermDebt
7500000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
63000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
251000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
256000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
262000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
267000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
203000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1302000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15262054
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10738626
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
27000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
97000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
262000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
58000

Files In Submission

Name View Source Status
0001564590-18-030291-index-headers.html Edgar Link pending
0001564590-18-030291-index.html Edgar Link pending
0001564590-18-030291.txt Edgar Link pending
0001564590-18-030291-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
phas-10q_20180930.htm Edgar Link pending
phas-20180930.xml Edgar Link completed
phas-20180930.xsd Edgar Link pending
phas-20180930_cal.xml Edgar Link unprocessable
phas-20180930_def.xml Edgar Link unprocessable
phas-20180930_lab.xml Edgar Link unprocessable
phas-20180930_pre.xml Edgar Link unprocessable
phas-ex311_46.htm Edgar Link pending
phas-ex312_47.htm Edgar Link pending
phas-ex321_49.htm Edgar Link pending
phas-ex322_48.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending